HRP20210076T1 - Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma - Google Patents

Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma Download PDF

Info

Publication number
HRP20210076T1
HRP20210076T1 HRP20210076TT HRP20210076T HRP20210076T1 HR P20210076 T1 HRP20210076 T1 HR P20210076T1 HR P20210076T T HRP20210076T T HR P20210076TT HR P20210076 T HRP20210076 T HR P20210076T HR P20210076 T1 HRP20210076 T1 HR P20210076T1
Authority
HR
Croatia
Prior art keywords
peptide
cancer
cell
use according
antibody
Prior art date
Application number
HRP20210076TT
Other languages
English (en)
Inventor
Andrea Mahr
Toni Weinschenk
Colette SONG
Oliver Schoor
Jens Fritsche
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1511792.2A external-priority patent/GB201511792D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of HRP20210076T1 publication Critical patent/HRP20210076T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)

Claims (13)

1. Peptid koji se sastoji od slijeda aminokiselina SEQ ID br. 9; ili njegovu farmaceutski prihvatljivu sol za uporabu u medicini.
2. Peptid za uporabu prema zahtjevu 1, koji navodi kako peptid uključuje nepeptidne vezove.
3. Peptid za uporabu prema zahtjevu 1 ili 2, pri čemu je navedeni peptid dio fuzijskog proteina, koji sadrži N-terminalne 80 aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii).
4. T-stanični receptor, po mogućnosti rekombinantni, topljiv ili na membranu vezan T-stanični receptor, koji je posebice reaktivan s HLA ligandom kada se veže za HLA molekulu, pri čemu se navedeni ligand sastoji od aminokiselinskog slijeda SEQ ID br. 9.
5. Antitijelo, posebice topljivo ili na membranu vezano antitijelo, koje posebice prepoznaje peptid za uporabu prema zahtjevu 1, po mogućnosti peptid za uporabu prema zahtjevu 1 kada se veže za MHC-molekule.
6. Nukleinska kiselina, koja kodira peptid za uporabu prema bilo kojem od zahtjeva 1 ili 3, zaTCR prema zahtjevu 4 ili antitijelo prema zahtjevu 5, opcionalno vezano na heterologni promotorski slijed ili ekspresijski vektor koji sadrži navedenu nukleinsku kiselinu.
7. Rekombinantna stanica domaćin koja sadrži peptid za uporabu prema zahtjevu 1 ili 3 ili nukleinsku kiselinu ili ekspresijski vektor prema zahtjevu 6, pri čemu navedena stanica domaćin po mogućnosti predstavlja antigen kao što je dendritička stanica ili gdje je navedena stanica domaćin po mogućnosti T-stanica ili NK stanica.
8. Metoda za proizvodnju peptida za uporabu prema bilo kojem zahtjevu 1 ili 3 ili za proizvodnju T-staničnih receptora prema zahtjevu 4 ili antitijelo prema zahtjevu 5, metoda koja obuhvaća kultiviranje stanice domaćina prema zahtjevu 7, koja predstavlja peptid za uporabu prema zahtjevu 1 ili ekspresivna nukleinska kiselina ili ekspresivni vektor prema zahtjevu 6 i izoliranje peptida ili TCR ili antitijelo od stanice domaćina ili njezinog medija za kultiviranje.
9. In vitro metoda za proizvodnju aktiviranih T-limfocita, metoda je koja obuhvaća kontaktiranje in vitro T-stanica humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen ili umjetnom konstrukcijom koja oponaša stanicu koja predstavlja antigen u vremenskom razdoblju dovoljnom da se aktiviraju navedene T-stanice na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu sa zahtjevom 1.
10. Aktivirani T-limfocit, proizveden metodom u skladu s patentnim zahtjevom 9 koji selektivno prepoznaje stanicu koja predstavlja polipeptid koji sadrži sekvenciju aminokiseline sukladno zahtjevu 1.
11. Farmaceutski sastav koji obuhvaća najmanje jedan aktivni sastojak, koji je odabran iz grupe koja se sastoji od peptida za uporabu prema bilo kojem od zahtjeva 1 ili 3, nukleinsku kiselinu ili ekspresivni vektor prema zahtjevu 6, stanicu prema zahtjevu 7, aktivirani T-limfocit prema zahtjevu 10 ili antitijelo prema zahtjevu 5 ili T-stanični receptor prema zahtjevu 4 i farmaceutski prihvatljivog nositelja i po potrebi farmaceutski prihvatljivog nositelja i/ili stabilizatora za uporabu u medicini.
12. Peptid za uporabu prema bilo kojem od zahtjeva 1 ili 3, nukleinska kiselina ili ekspresivni vektor prema zahtjevu 6, stanica prema zahtjevu 7, aktivirani T-limfocit prema zahtjevu 10 ili antitijelo prema zahtjevu 5 ili T-stanični receptor prema zahtjevu 4 ili farmaceutski sastav za uporabu prema zahtjevu 11 za uporabu u medicini, po mogućnosti za upotrebu u liječenju karcinoma.
13. Peptid za uporabu prema bilo kojem od zahtjeva 1 ili 3, nukleinska kiselina ili ekspresivni vektor prema zahtjevu 6, stanica prema zahtjevu 7, aktivirani T-limfocit prema zahtjevu 10 ili antitijelo prema zahtjevu 5 ili T-stanični receptor prema zahtjevu 4 ili farmaceutski sastav za uporabu prema zahtjevu 11 za uporabu prema zahtjevu 12, pri čemu je karcinom karcinom jajnika, nemalostanični karcinom pluća, malostanični karcinom pluća, karcinom bubrega, karcinom mozga, karcinom debelog crijeva ili rektuma, karcinom želuca, karcinom jetre, karcinom pankreasa, karcinom prostate, leukemija, karcinom dojke, karcinom Merkelovih stanica, melanom, karcinom ezofalgusa, karcinom mjehura, karcinom uterusa, karcinom žučnog mjehura, karcinom žučnih vodova ili drugi karcinom koji pokazuje prekomjernu ekspresiju proteina iz kojeg je izveden peptid prema SEQ ID br. 9.
HRP20210076TT 2015-07-06 2021-01-14 Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma HRP20210076T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562188870P 2015-07-06 2015-07-06
GBGB1511792.2A GB201511792D0 (en) 2015-07-06 2015-07-06 Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
EP16736073.4A EP3319985B1 (en) 2015-07-06 2016-07-05 Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
PCT/EP2016/065812 WO2017005733A2 (en) 2015-07-06 2016-07-05 Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers

Publications (1)

Publication Number Publication Date
HRP20210076T1 true HRP20210076T1 (hr) 2021-05-14

Family

ID=56368954

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210076TT HRP20210076T1 (hr) 2015-07-06 2021-01-14 Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma

Country Status (33)

Country Link
US (21) US10487132B2 (hr)
EP (2) EP4321172A3 (hr)
JP (3) JP6944382B2 (hr)
KR (1) KR20180026758A (hr)
CN (2) CN107912043B (hr)
AU (3) AU2016289754B2 (hr)
BR (1) BR112017028363A2 (hr)
CA (2) CA3221001A1 (hr)
CL (7) CL2017003361A1 (hr)
CO (1) CO2017012886A2 (hr)
CR (3) CR20230563A (hr)
DK (1) DK3319985T3 (hr)
EA (1) EA201792671A1 (hr)
ES (1) ES2841507T3 (hr)
HK (1) HK1255542A1 (hr)
HR (1) HRP20210076T1 (hr)
HU (1) HUE052628T2 (hr)
IL (2) IL313594A (hr)
LT (1) LT3319985T (hr)
MA (1) MA51531A (hr)
MD (1) MD3319985T2 (hr)
MX (2) MX2017017148A (hr)
MY (1) MY188354A (hr)
PE (3) PE20231014A1 (hr)
PH (1) PH12018500004A1 (hr)
PL (1) PL3319985T3 (hr)
PT (1) PT3319985T (hr)
RS (1) RS61203B1 (hr)
SG (1) SG10202001668PA (hr)
SI (1) SI3319985T1 (hr)
TW (2) TWI776332B (hr)
UA (1) UA124411C2 (hr)
ZA (1) ZA201707810B (hr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109628591B (zh) * 2018-12-04 2022-04-15 南方医科大学南方医院 用于肺腺癌预后预测的标志物
CN112007167B (zh) * 2020-08-29 2023-01-24 南京中医药大学 蟾酥多肽在作为蟾蜍甾烯促渗剂中的应用
CN112812197B (zh) * 2021-01-11 2022-05-31 中国药科大学 一种兰州百合多糖及其制备方法和应用
CN114057860B (zh) * 2021-11-09 2023-10-20 中国科学技术大学 特定组氨酸甲基化修饰的s100a9蛋白免疫原、多克隆抗体及其制备方法
CN114717191B (zh) * 2022-04-26 2023-06-16 兰州大学第一医院 一株人肝内胆管癌细胞株icc-x3及其应用
CN115322967B (zh) * 2022-06-13 2023-08-08 浙江省人民医院 一种永生化人甲状腺乳头状癌成纤维细胞株及其构建方法和应用
CN114957399B (zh) * 2022-06-29 2023-05-09 湖北工业大学 一种多肽、多肽衍生物及其在制备抗肿瘤药物中的应用
CN116183920B (zh) * 2022-09-22 2023-10-20 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于检测鼻咽癌预后的抗体组合、系统及应用
CN116144772B (zh) * 2022-11-18 2023-08-25 昆明医科大学第一附属医院 一种Hsa_circ_0006117在制备治疗肺腺癌药物中的应用
CN115737619A (zh) * 2022-11-21 2023-03-07 深圳承启生物科技有限公司 一种用于抑制肿瘤的药物靶点、用途及口服药物
CN116676334A (zh) * 2023-02-08 2023-09-01 深圳大学 抑郁症动物模型的构建方法
CN117843721B (zh) * 2024-03-07 2024-05-10 鲁东大学 一种扇贝源抗氧化肽及其制备方法与应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
ES487106A0 (es) 1978-12-22 1981-05-16 Biogen Nv Un metodo para producir al menos un polipeptido que muestra antigenicidad de hbv
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
ES2108460T3 (es) 1993-06-03 1997-12-16 Therapeutic Antibodies Inc Fragmentos de anticuerpos en terapeutica.
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
PT879282E (pt) 1996-01-17 2003-11-28 Imp College Innovations Ltd Imunoterapia utilizando linfocitos t citotoxicos (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2287254A1 (en) * 1997-04-21 1998-10-29 Schering Corporation Mammalian cytokines; related reagents and methods
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
CA2296287A1 (en) 1997-08-01 1999-02-11 Genset 5' ests for secreted proteins expressed in prostate
IL143593A0 (en) 1998-12-23 2002-04-21 Genentech Inc Il-1 related polypeptides
AU785493B2 (en) 2000-03-27 2008-01-03 Technion Research & Development Foundation Ltd. Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CN101712721A (zh) 2000-06-05 2010-05-26 阿尔托生物科学有限公司 T细胞受体融合物及共轭物以及其使用方法
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
JP4436319B2 (ja) 2002-10-09 2010-03-24 メディジーン リミテッド 単鎖組換えｔ細胞レセプター
US7378495B2 (en) * 2002-10-21 2008-05-27 Pevion Biotech, Ltd. PTH-rP related peptide cancer therapeutics
EP2048159B1 (en) 2002-11-09 2014-01-01 Immunocore Ltd. T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US20040220094A1 (en) 2003-05-01 2004-11-04 Skinner Keith K. Inverse agonist and agonist peptides that stimulate/inhibit hair growth
US8053183B2 (en) * 2005-07-27 2011-11-08 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
DK1760089T3 (da) 2005-09-05 2009-11-16 Immatics Biotechnologies Gmbh Tumor-associeret peptides bindende til human leukocyte antigen (HLA) class I eller II molecules og relateret anti-cancer vaccine
DK1806359T3 (da) 2005-09-05 2010-06-14 Immatics Biotechnologies Gmbh Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
WO2008013934A2 (en) * 2006-07-27 2008-01-31 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP2444418A3 (en) * 2006-09-08 2012-08-08 Amgen, Inc IL-1 Family Variants
PT2660248E (pt) * 2007-07-27 2015-10-12 Immatics Biotechnologies Gmbh Nova imunoterapia para tumores neuronais e cerebrais
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
NO2119726T3 (hr) * 2008-05-14 2015-05-23
EP2172211B1 (en) * 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
WO2010120554A1 (en) * 2009-04-01 2010-10-21 The Regents Of The University Of California Detecting and treating breast cancer resistance to egfr inhibitors
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
CA2816225A1 (en) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
WO2014071978A1 (en) 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Nucleic acids encoding chimeric polypeptides for library screening
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI819228B (zh) * 2013-08-05 2023-10-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八）

Also Published As

Publication number Publication date
TW202124430A (zh) 2021-07-01
US20200157176A1 (en) 2020-05-21
CR20230563A (es) 2024-01-22
US20210024609A1 (en) 2021-01-28
CL2021000979A1 (es) 2021-09-10
IL256303B1 (en) 2024-10-01
CL2017003361A1 (es) 2018-05-04
US20220119487A1 (en) 2022-04-21
US11359003B2 (en) 2022-06-14
US20220112266A1 (en) 2022-04-14
US11939366B2 (en) 2024-03-26
AU2021200800A1 (en) 2021-03-04
SG10202001668PA (en) 2020-04-29
AU2021200800B2 (en) 2022-08-18
TWI776332B (zh) 2022-09-01
CA3221001A1 (en) 2017-01-12
MD3319985T2 (ro) 2021-01-31
JP6944382B2 (ja) 2021-10-06
US20220119485A1 (en) 2022-04-21
US11932678B2 (en) 2024-03-19
RS61203B1 (sr) 2021-01-29
PE20240778A1 (es) 2024-04-17
US11999774B2 (en) 2024-06-04
AU2016289754A1 (en) 2017-11-30
SI3319985T1 (sl) 2021-01-29
US20220119484A1 (en) 2022-04-21
JP2018519825A (ja) 2018-07-26
CL2023000708A1 (es) 2023-08-18
CO2017012886A2 (es) 2018-03-09
IL313594A (en) 2024-08-01
BR112017028363A2 (pt) 2018-08-28
HUE052628T2 (hu) 2021-05-28
US20200010531A1 (en) 2020-01-09
AU2022205209B2 (en) 2024-05-09
US20220119486A1 (en) 2022-04-21
CN113880938A (zh) 2022-01-04
MY188354A (en) 2021-12-02
EA201792671A1 (ru) 2018-06-29
ZA201707810B (en) 2018-11-28
US20220098276A1 (en) 2022-03-31
CL2021000980A1 (es) 2021-09-10
LT3319985T (lt) 2020-12-28
UA124411C2 (uk) 2021-09-15
PL3319985T3 (pl) 2021-05-04
US11401319B2 (en) 2022-08-02
TW202222825A (zh) 2022-06-16
MA51531A (fr) 2020-11-11
US20220106379A1 (en) 2022-04-07
CN107912043B (zh) 2022-02-18
JP2022020614A (ja) 2022-02-01
US20220098277A1 (en) 2022-03-31
CN107912043A (zh) 2018-04-13
US11608370B2 (en) 2023-03-21
US20220135648A1 (en) 2022-05-05
US10829537B2 (en) 2020-11-10
US20220135647A1 (en) 2022-05-05
US20200291088A1 (en) 2020-09-17
CR20170579A (es) 2018-05-25
US20190315832A1 (en) 2019-10-17
CL2021000982A1 (es) 2021-09-10
US10703795B2 (en) 2020-07-07
PT3319985T (pt) 2021-01-06
EP4321172A3 (en) 2024-08-21
PE20180259A1 (es) 2018-02-05
JP2024041841A (ja) 2024-03-27
CL2023000706A1 (es) 2023-08-18
EP3736283A1 (en) 2020-11-11
IL256303A (en) 2018-02-28
US20210277087A1 (en) 2021-09-09
MX2021013003A (es) 2022-01-18
HK1255542A1 (zh) 2019-08-23
CR20230562A (es) 2024-01-22
CL2021000981A1 (es) 2021-09-10
ES2841507T3 (es) 2021-07-08
EP4321172A2 (en) 2024-02-14
US10626162B2 (en) 2020-04-21
US20220106380A1 (en) 2022-04-07
US20210277086A1 (en) 2021-09-09
US20220098275A1 (en) 2022-03-31
KR20180026758A (ko) 2018-03-13
DK3319985T3 (da) 2021-01-04
US10487132B2 (en) 2019-11-26
MX2017017148A (es) 2018-02-23
CA2991396A1 (en) 2017-01-12
US20210277088A1 (en) 2021-09-09
PH12018500004A1 (en) 2018-07-09
AU2022205209A1 (en) 2022-08-04
AU2016289754B2 (en) 2021-02-18
US20220135646A1 (en) 2022-05-05
PE20231014A1 (es) 2023-07-05

Similar Documents

Publication Publication Date Title
HRP20201281T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma
HRP20210076T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma
HRP20210709T1 (hr) Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma
HRP20210698T1 (hr) Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
HRP20202019T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
HRP20201467T1 (hr) Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom
JP2020182458A5 (hr)
JP2020198875A5 (hr)
JP2020191862A5 (hr)
JP2019515650A5 (hr)
HRP20192262T1 (hr) Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc)
AR121383A2 (es) Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres
HRP20160915T1 (hr) Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga
RU2020113032A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
JP2019516663A5 (hr)
HRP20230878T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raznih karcinoma (seq id 25 - mrax5-003)
AR106920A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer
JP2021101700A5 (hr)
HRP20230512T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma
JP2017518037A5 (hr)
MX2021001163A (es) Péptidos multimerizantes derivados del dominio de pliegue kelly roll del capsómero pentagonal de adenovirus.
HRP20210528T1 (hr) Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma
AR110857A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
JP2019536426A5 (hr)
HRP20191671T1 (hr) Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)